75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Condensed Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Statements of Operations
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Statements of Comprehensive Loss
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Statements of Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Condensed Statements of Cash Flows
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - The Company
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Fair Value Measurements and Marketable Securities
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Property and Equipment, Net
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Accrued and Other Current Liabilities
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Research and Collaboration Arrangements
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - License Arrangements
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Long Term Debt
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Common Stock
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Stock-based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Common Stock Warrants
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Pre-funded Warrants
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Net Loss Per Share, Basic and Diluted
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Derivative Liability
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - California Institute for Regenerative Medicine Award
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - 401(K) Plan
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Fair Value Measurements and Marketable Securities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Property and Equipment, Net (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Accrued and Other Current Liabilities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Research and Collaboration Arrangements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Long Term Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Common Stock (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Stock-based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Net Loss Per Share, Basic and Diluted (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - The Company - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenues by Geographic Region (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Fair Value Measurements and Marketable Securities - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Fair Value Measurements and Marketable Securities - Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Aggregate fair values of marketable securities with unrealized losses and gains (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Property and Equipment, Net - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Research and Collaboration Arrangements - Summary of Collaboration and License Revenue and Deferred revenue (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Research and Collaboration Arrangements - CFF - Additional Information (Details 1) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Research and Collaboration Arrangements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - License Arrangements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Commitments and Contingencies - Summary of Supplemental Information Related to Operating Leases (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Long Term Debt - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Long Term Debt - Summary of Future Principal Payments due under Hercules Loan Facility (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Long Term Debt - Summary of Carrying Value of Hercules Loan Facility (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Common Stock - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Common Stock - Schedule of Common Share Reserved for Future Issuance (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996075 - Disclosure - Stock-based Compensation - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996085 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Units (RSU) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996095 - Disclosure - Stock-based Compensation - Summary of Stock Options Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996105 - Disclosure - Stock-based Compensation - Schedule of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996115 - Disclosure - Stock-based Compensation - Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996125 - Disclosure - Common Stock Warrants - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996135 - Disclosure - Pre-funded Warrants - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996145 - Disclosure - Net Loss Per Share, Basic and Diluted - Computation of Basic and Diluted Net Loss Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996155 - Disclosure - Net Loss Per Share, Basic and Diluted - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996165 - Disclosure - Net Loss Per Share, Basic and Diluted - Outstanding Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996175 - Disclosure - Derivative Liability - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996185 - Disclosure - California Institute for Regenerative Medicine Award - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996195 - Disclosure - Related Party Transactions - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996205 - Disclosure - 401(K) Plan - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996215 - Disclosure - Segment Information - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996225 - Disclosure - Segment Information - Schedule Of Disaggregated Amounts That Comprise Research and Development Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Concentration Risk Type [Axis]
Concentration Risk Type
Contingent payments development milestones.
Contingent payments development milestones
Contingent payments development milestones
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred Stock, Shares Issued
Preferred stock, shares issued
Statement of Financial Position Location, Balance [Domain]
Defined Benefit Plan, Plan Assets, Contributions by Employer
Employer contribution
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Ending Balance
Beginning Balance
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accounts Payable, Total
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental disclosures of noncash investing and financing information
Long-term debt, net
Long-Term Debt, Excluding Current Maturities
Long-term debt, net
Long-term debt, net
Plan Name [Axis]
Plan Name
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Individual securities held in an unrealized loss position for 12 months or greater
Aggregate fair value of marketable securities in a continuous loss position for more than twelve months
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Fair Value Measurements and Marketable Securities [Abstract]
Fair value measurements and marketable Securities.
JAPAN
Japan
License arrangements.
License Arrangements [Text Block]
License Arrangements
Operating Expenses [Abstract]
Operating expenses:
Fair Value, Inputs, Level 2 [Member]
Level 2
Other impairment charge related to marketable securities.
Other Impairment Charge Related To Marketable Securities
Other impairment charges related to marketable securities
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Common Stock, Shares Authorized
Common stock, shares authorized
Additional funding committed.
Additional Funding Committed
Additional funding upon acceptance of investigational New Drug application
Product and Service
Product and Service [Axis]
Fair Value by Liability Class [Domain]
Fair Value by Liability Class
Document Fiscal Period Focus
Document Fiscal Period Focus
Debt Instrument, Interest Rate, Stated Percentage
Debt interest rate per annum
Entity Shell Company
Entity Shell Company
Other Accrued Liabilities, Current
Other accrued expenses
California Institute For Regenerative Medicine [Member]
California institute for regenerative medicine.
California Institute for Regenerative Medicine
Segment Reporting, Policy [Policy Text Block]
Segment Information
Cash and Cash Equivalent
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Cash and Cash Equivalents
Number Of Prefunded Warrant Holders
Number of prefunded warrant holders.
Number of prefunded warrant holders
Schedule of Maturities of Long-Term Debt [Table Text Block]
Summary of Future Principal Payments due under Hercules Loan Facility
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Debt Instrument Outstanding Principal Amount
Debt instrument outstanding principal amount.
Principal outstanding
Common Stock, Shares, Issued
Common stock, shares, issued
Common Stock, Shares, Issued, Total
Term Loans Aggregate Principal Amount Tranches Five [Member]
Term loans aggregate principal amount tranches five.
Term Loans Aggregate Principal Amount Tranches Five
Asset Class [Domain]
Asset Class
Statement [Table]
Statement [Table]
Number of installments to pay actual award.
Number Of Installments To Pay Actual Award
Number of installments to pay actual award
Lease commencement date.
Lease Commencement Date
Lease commencement date
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent
Employee purchase price of common stock as percentage of fair market value
Amount paid non-refundable license fees.
Amounts Paid Non Refundable License Fees
Amount paid non-refundable license fee
Statement [Line Items]
Statement [Line Items]
Warrant [Member]
Common Stock Warrants
Entity Filer Category
Entity Filer Category
Liabilities and Equity
Total liabilities and stockholders’ equity
Debt Instrument [Line Items]
Payables and Accruals [Abstract]
Credit Concentration Risk [Member]
Credit Concentration Risk
Payments to Acquire Marketable Securities
Purchase of marketable securities
Payments to Acquire Marketable Securities, Total
Purchase of marketable securities
Long-Term Debt, Maturity, Year Three
2029
Five Eight Five Eight Horton Street Lease [Member]
Five eight five eight horton street lease.
5858 Horton Street Lease
RA Capital Healthcare Fund, L.P [Member]
RA Capital Healthcare Fund, L.P.
RA Capital Healthcare Fund, L.P
Long-Lived Tangible Asset [Axis]
Long-Lived Tangible Asset
Summary of supplemental information related to operating leases
Summary Of Supplemental Information Related to Operating Leases [Table Text Block]
Summary of Supplemental Information Related to Operating Leases
Debt Instrument, Frequency of Periodic Payment
Debt instrument, frequency of periodic payment
Prepaid Expenses and Other Current Assets [Member]
Prepaid and Other Current Assets
Derivative [Line Items]
Derivative [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure
Cash
Shares Issued, Price Per Share
Stock sold and issued price per share
Stock issued price per share
Stock Options Issued and Outstanding
Investment Income, Interest
Interest income
Geographical [Domain]
Long Term Debt Maturities Repayments Of Principal After Year Four
Long term debt maturities repayments of principal after year four.
Thereafter
Non-refundable license fee payable upon execution.
Non Refundable License Fee Payable Upon Execution
Non-refundable license fee payable upon execution
Share based compensation arrangement by share based payment award number of additional shares available for grant.
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Available For Grant
Number of additional shares available for grant
Aggregate fair value of marketable securities in unrealized gain position.
Aggregate fair value of marketable securities in unrealized gain position
Aggregate fair value of marketable securities in unrealized gain position
Debt Securities, Available-for-Sale, Term
Maturity period of marketable securities
Additional Paid in Capital, Common Stock
Additional Paid in Capital, Common Stock, Ending Balance
Additional Paid in Capital, Common Stock, Beginning Balance
Additional paid-in-capital
Otsuka Pharmaceutical Company Ltd [Member]
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd
Pre Funded Warrants [Text Block]
Pre funded warrants.
Pre-funded Warrants
Defined Contribution Plan [Text Block]
401(K) Plan
Sales Agreement
Sales Agreement [Member]
Sales agreement.
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Property, Plant and Equipment [Line Items]
Property Plant And Equipment [Line Items]
Concentration Risk [Table]
Share Repurchase Program [Axis]
Proceeds From Issuance of Employee Stock Plans
Proceeds from issuance of employee stock plans.
Issuance of common stock - 2020 ESPP
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Number of Shares Underlying Outstanding Options, granted
Disaggregation of Revenue [Table]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Computation of Basic and Diluted Net Loss Per Share
Percentage of equity interests issued as common stock.
Percentage Of Equity Interests Issued As Common Stock
Percentage of equity interests issued as common stock
Earnings Per Share, Basic
Net loss per share, basic
Earnings Per Share, Basic, Total
Disaggregation of Revenue [Table Text Block]
Summary of Collaboration and License Revenue and Deferred Revenue
JefferiesLimitedLiabilityCompanyMember
Jefferies Limited Liability Company [Member]
Jefferies limited liability company.
Jefferies LLC
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Number of options outstanding
Number of Shares Underlying Outstanding Options, Balances at December 31, 2025
Number of Shares Underlying Outstanding Options, Balances at June 30, 2026
Long Term Debt
Debt, Policy [Policy Text Block]
Accrued clinical and preclinical study costs.
Accrued Clinical And Preclinical Study Costs
Accrued clinical and preclinical study costs
Liabilities, Current
Total current liabilities
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Summary of Changes in Fair Value of Level 3 Financial Instruments
Share Repurchase Program [Domain]
Lessee Operating Lease Incremental Borrowing Rate
Lessee Operating Lease Incremental Borrowing Rate
Incremental borrowing rate
Schedule of accrued and other current liabilities.
Schedule Of Accrued And Other Current Liabilities [Table Text Block]
Summary of Accrued and Other Current Liabilities
Payments of Debt Issuance Costs
Payment of debt issuance costs
Term Loans First Four Tranches [Member]
Term loans first four tranches.
Term Loans First Four Tranches
Summary of significant accounting policies line items.
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
UC Agreements.
U C Agreements [Member]
UC Agreements
Equity, Attributable to Parent [Abstract]
Stockholders’ equity
Entity Small Business
Entity Small Business
Initial facility fee
Line of Credit Facility, Commitment Fee Amount
Increase (Decrease) in Accrued Liabilities
Accrued and other liabilities
Increase (Decrease) in Accrued Liabilities, Total
Upfront cash payment
Upfront Cash Payment
Upfront cash payment.
David Kirn
David Kirn [Member]
David Kirn.
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Beginning Balance
Accumulated deficit
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Amount obligated to pay a non-refundable license fee annually.
Amount Obligated To Pay Non Refundable License Fee Annually
Non-refundable license fee payable annually
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Number of Shares Underlying Outstanding Options, forfeited
Sale of Stock, Price Per Share
Common stock offering price
Future sales based milestone payment expected payments multiples of actual award received.
Future Sales Based Milestone Payment Expected Payments Multiples of Actual Award Received
Expected payments multiples to equal actual award received
Share-Based Payment Arrangement [Text Block]
Stock-based Compensation
Increase decrease in right of use asset.
Increase Decrease in Right Of Use Asset
Increase in right-of-use asset
Percentage of debt minimum qualified cash balance requirement
Percentage Of Debt Minimum Qualified Cash Balance Requirement
Percentage of debt minimum qualified cash balance requirement.
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Defined Contribution Plan [Table]
Defined Contribution Plan [Table]
Lease Contractual Term [Axis]
Contract with Customer, Liability
Deferred revenue
Contract with Customer, Liability, Total
Total deferred revenue
Amendment Flag
Amendment Flag
Product and Service [Domain]
Product and Service
Warrant expires year.
Warrant Expires Year
Warrant expiration year
Warrants to purchase shares of common stock
Warrants shares exercised
Warrant shares become exercisable
Concentration Risk [Line Items]
Liabilities and Equity [Abstract]
Liabilities and Stockholders’ Equity
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash used in operating activities
Increase (Decrease) in Operating Lease Liability
Operating lease liabilities
Increase in lease liability
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Common Stock [Member]
Common Stock
Two Thousand Twenty Five Offering [Member]
Two Thousand Twenty Five Offering.
2025 Offering
Long-Term Debt, Maturity, Year One
2027
Lessee, Operating Lease, Liability, to be Paid, Year Three
2029
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total
Less: Accumulated depreciation and amortization
Debt Securities, Available-for-Sale [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Research and Development Arrangement, Contract to Perform for Others, Type
Upfront consideration payment.
Upfront Consideration Payment
Upfront consideration payment
Debt Instrument, Interest Rate, Effective Percentage
Debt effective interest rate
Entity Address, Address Line One
Entity Address, Address Line One
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Summary of Assumptions Used in Black-Scholes Valuation Model to Estimate Fair Value of Stock Options
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV
Earnings Per Share [Abstract]
Collaborative Arrangement Achieved Cumulative Milestones
Collaborative arrangement achieved cumulative milestones.
Collaborative arrangement achieved cumulative milestones
Recently Issued Accounting Pronouncements Not Yet Adopted
Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]
Recently issued accounting pronouncements not yet adopted.
Statement of Financial Position Location, Balance [Axis]
Unpaid Debt Offering Costs in Accrued and Other Current Liabilities
Unpaid debt offering costs in accrued and other current liabilities.
Unpaid debt offering costs in accrued and other current liabilities
Operating lease right-of-use assets, net
Operating lease, right-of-use assets
Operating lease right-of-use ("ROU") assets
4D-150
Four D To One Five Zero [Member]
Four d to one five zero.
Class of Warrant or Right [Axis]
Class of Warrant or Right
Document Type
Document Type
Two thousand twenty incentive award plan.
Two Thousand Twenty Incentive Award Plan [Member]
2020 Incentive Award Plan
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Stock Purchase Agreement [Member]
Stock purchase agreement member.
Stock Purchase Agreement
Hercules Loan Facility
Loan and Security Agreement [Member]
Loan and security agreement.
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Entity Central Index Key
Entity Central Index Key
Award From Regenerative Medicine Institute [Table]
Award from regenerative medicine institute.
Grant awarded
Grant Award
Grant award.
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net increase (decrease) in cash and cash equivalents
Fair value of warrant shares
Fair Value Adjustment of Warrants
Additional investment in cash.
Additional Investment in Cash
Additional investment in cash
Reignite agreement.
Reignite Agreement [Member]
Reignite Agreement
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities
Two thousand fifteen equity incentive plan.
Two Thousand Fifteen Equity Incentive Plan [Member]
2015 Equity Incentive Plan
Common Stock, Par or Stated Value Per Share
Common stock, par value
Operating Costs and Expenses
Related party expenses
Operating Costs and Expenses, Total
Proceeds from Issuance of Warrants
Issuance of pre-funded warrants
Operating Lease, Right-of-Use Asset, Periodic Reduction
Amortization of right-of-use assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Expected volatility, maximum
Asset Acquisition, Contingent Consideration, Liability
Liability related to contingent consideration
Asset Acquisition, Contingent Consideration, Liability, Total
Debt Securities, Available-for-sale, Amortized Cost
Amortized Cost Basis
Amortized Cost Basis
Defined Contribution Plan Disclosure [Line Items]
Defined Contribution Plan Disclosure [Line Items]
Debt Securities, Available-for-Sale
Fair Value
Debt Securities, Available-for-sale, Total
Debt Instruments [Abstract]
Unsatisfied or partially unsatisfied performance obligations
Contract With Customer Unsatisfied or Partially Unsatisfied Performance Obligation
Contract with customer unsatisfied or partially unsatisfied performance obligation.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Issuance of common stock upon exercise of stock options (in shares)
Number of Shares Underlying Outstanding Options, exercised
Debt Disclosure [Abstract]
Derivative [Table]
Derivative [Table]
Transportation Equipment
Transportation Equipment [Member]
Organization and nature of business.
Organization And Nature Of Business [Table]
Organization And Nature Of Business [Table]
Two Thousand Twenty Five Employment Inducement Plan [Member]
Two Thousand Twenty Five Employment Inducement Plan [Member]
2025 Employment Inducement Plan
Marketable Securities
Total marketable securities
Accrued Liabilities, Current
Accrued and other current liabilities
Total accrued and other current liabilities
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
Schedule of Long-Term Debt Instruments [Table]
Document Quarterly Report
Document Quarterly Report
Entity Address, State or Province
Entity Address, State or Province
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of Shares, Unvested Ending Balance
Number of Shares, Unvested Beginning Balance
Regenerative Medicine Award Disclosure [Text Block]
Regenerative medicine award.
California Institute for Regenerative Medicine Award
Line of Credit Facility, Remaining Borrowing Capacity
Remaining borrowing capacity
Financial Liabilities Fair Value Disclosure
Financial Liabilities Fair Value Disclosure, Total
Liabilities
Fair Value
Preferred Stock, Shares Outstanding
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Total comprehensive loss
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Gross Unrealized Gains
Common Stock, Capital Shares Reserved for Future Issuance
Common stock reserved
Number of shares reserved for issuance
Class of Warrant or Right [Domain]
Class of Warrant or Right
Geographical [Axis]
Line of Credit Facility, Lender [Domain]
Contract with Customer, Liability, Revenue Recognized
Revenue included in deferred revenue at the beginning of the current year
Revenue recognized
Accounts Receivable [Member]
Accounts Receivable
Marketable Securities, Current
Marketable securities
Marketable Securities, Current, Total
Current Marketable Securities
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Summary of Stock-based Compensation Expense for Employees and Nonemployees by Function
Increase in shares available for issuance percentage
Increase in Shares Available for Issuance Percentage
Increase in shares available for issuance percentage.
Award From California Institute For Regenerative Medicine [Abstract]
Award from california institute for regenerative medicine.
Term Loans Aggregate Principal Amount Tranches Initial [Member]
Term loans aggregate principal amount tranches initial.
Term Loans Aggregate Principal Amount Tranches Initial
Collaborative Arrangement Disclosure [Text Block]
Research and Collaboration Arrangements
Nature of Expense [Axis]
Proceeds from Sale and Maturity of Marketable Securities
Maturities of marketable securities
Proceeds from Sale and Maturity of Marketable Securities, Total
Long-Term Debt, Maturity, Remainder of Fiscal Year
Remainder of 2026
Share based compensation arrangement by share based payment award percentage of outstanding stock increased annually for future issuance.
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Increased Annually For Future Issuance
Percentage of common stock outstanding increased annually for future issuance
Collaborative arrangements special term.
Collaborative Arrangements Special Term
Collaborative arrangements special term
Property, Plant and Equipment [Abstract]
Other Assets, Noncurrent
Other Assets, Noncurrent, Total
Other non-current assets
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Less: unamortized discount and debt issuance costs
Potential Cash Payment upon Achievement of Certain Late-Stage Regulatory Milestones
Potential cash payment upon achievement of certain late-stage regulatory milestones.
Potential cash payment for regulatory milestones
Antidilutive Securities [Axis]
Antidilutive Securities
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Number of Shares Underlying Outstanding Options, expired
Number of Shares Underlying Outstanding Options, expired
Fair value liabilities level one and level two transfers amount.
Fair Value Liabilities Level One And Level Two Transfers Amount
Liabilities, Level 1 and Level 2 transfers
Related Party Transaction [Axis]
Related Party Transaction
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Gain (Loss)
Customer [Domain]
Customer
Cash [Member]
Class of Warrant or Right, Nominal Exercise Price of Warrants or Rights
Class of warrant or right, nominal exercise price of warrants or rights.
Nominal exercise price
Cash and Cash Equivalents [Domain]
Preferred Stock, Value, Issued
Preferred stock, $0.0001 par value, 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Number of common shares exchanged for prefunded warrants
Number of common shares exchanged for pre-funded warrants.
Debt Instrument, Maturity Date
Debt instrument, maturity date
Estimated Cost Sharing and Reimbursement Amount Due
Estimated cost sharing and reimbursement amount due.
Estimated cost sharing and reimbursement amount due
Minimum [Member]
Minimum [Member]
Minimum
Financial Instrument [Axis]
Assets, Current [Abstract]
Current assets:
Issuance of common stock upon exercise of equity warrants (in shares)
Issuance of Common Stock Upon Exercise of Equity Warrants
Issuance of common stock upon exercise of equity warrants
Maximum Eligible Potential Regulatory and Commercial Milestone Payments
Maximum eligible potential regulatory and commercial milestone payments.
Eligible potential milestone payments
Fair Value, Inputs, Level 3 [Member]
Level 3
Segment Reporting [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Fair Value Hierarchy for Financial Assets and Financial Liabilities Measured at Fair Value on Recurring Basis
Product achieving development or commercial status.
Product Achieving Development Or Commercial Status [Member]
Product Achieving Development or Commercial Status
Gross Proceeds from Issuance of Common Stock
Gross proceeds from issuance of common stock.
Aggregate gross sales proceeds from common stock
Interim Period, Costs Not Allocable [Domain]
Liabilities, Current [Abstract]
Current liabilities
Stock issued during period shares stock options exercised and vesting of restricted stock units.
Stock Issued During Period Shares Stock Options Exercised And Vesting of Restricted Stock Units
Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)
Cystic Fibrosis Foundation [Member]
Cystic Fibrosis Foundation [Member]
Cystic Fibrosis Foundation
CFF
Related Party Transactions [Abstract]
Shares, Outstanding
Stockholders' Equity, ending balances (in shares)
Stockholders' Equity, beginning balances (in shares)
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]
Summary of Aggregate Fair Values of Marketable Securities with Unrealized Losses and Gains
Lessee, Operating Lease, Renewal Term
Lease renewal term
Accounts Payable
Accounts Payable and Accrued Liabilities [Member]
Commitments and Contingencies
Commitments and contingencies (Note 8)
Collaboration arrangements upfront payment received.
Collaboration Arrangements Upfront Payment Received
Upfront payments received
General and Administrative Expense [Member]
General and Administrative
Operating Lease, Liability
Present value of future minimum lease payments
Present value of future minimum lease payments
Operating lease liability
Debt Instrument, Basis Spread on Variable Rate
Debt instrument, basis spread on variable rate
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark
Marketable Securities, Noncurrent
Marketable securities, long-term
Marketable Securities, Noncurrent, Total
Non-Current Marketable Securities
Long-Term Debt, Maturity, Year Two
2028
Capital Expenditures Incurred but Not yet Paid
Purchases of property and equipment in accrued and other current liabilities
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Potential Cash Payment upon Achievement of Certain Late-Stage Milestones
Potential cash payment upon achievement of certain late-stage milestones.
Potential cash payment upon achievement of certain late-stage milestones
Lease Contractual Term [Domain]
Warrant vesting period.
Warrant Vesting Period
Warrant vesting period
License agreement with university of Pennsylvania.
License Agreement With University Of Pennsylvania [Member]
License Agreement for sCFH with University of Pennsylvania
Long-Term Debt, Type [Domain]
Weighted Average Number of Shares Outstanding, Basic
Weighted-average shares outstanding used in computing net loss per share, basic
Weighted Average Number of Shares Outstanding, Basic, Total
Revenue from External Customers by Geographic Areas [Table Text Block]
Schedule of Revenues by Geographic Region
Exchange of common stock for pre-funded warrants
Stock Issued During Period Value Of Common Stock For Pre-funded Warrants Conversions
Stock issued during period value of common stock for pre-funded warrants conversions.
Scenario [Axis]
Document Information [Line Items]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Long-Lived Tangible Asset [Domain]
Long-Lived Tangible Asset
Option exercise fees payable to related party.
Option Exercise Fees Payable to Related Party
Option exercise fee
Five Eight Five Eight Horton Lease [Member]
Five eight five eight horton lease.
5858 Horton Lease
Subsequent Events [Text Block]
Subsequent Events
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation expense
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Equity, Attributable to Parent
Stockholders' Equity, ending balances
Stockholders' Equity, beginning balances
Total stockholders’ equity
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Basis of Accounting, Policy [Policy Text Block]
Basis of Presentation
Statement of Stockholders' Equity [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Number of warrant shares issued.
Number Of Warrant Shares Issued
Number of warrant shares issued
Term Loans Aggregate Principal Amount Tranches Three [Member]
Term loans aggregate principal amount tranches three.
Term Loans Aggregate Principal Amount Tranches Three
Aggregate unrealized loss.
Aggregate Unrealized Loss
Aggregate unrealized loss
Use of Estimates, Policy [Policy Text Block]
Use of Estimates and Judgments
Over-Allotment Option [Member]
Exercise of Overallotment Option
Leasehold Improvements [Member]
Leasehold Improvements
UNITED STATES
United States
Debt Instrument, Name [Domain]
Percentage of End of term charge payment
Percentage of end-of-term charge
Percentage of end of term charge payment.
Long-Term Debt, Maturity, Year Four
2030
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Two thousand twenty four follow on public offering.
Two Thousand Twenty Four Follow On Public Offering [Member]
2024 Follow On Public Offering
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Plan Name [Domain]
Plan Name
Organization and nature of business.
Organization And Nature Of Business [Line Items]
Organization And Nature Of Business [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Percentage of equity interest upon closing of first qualified financing at option.
Percentage of equity interest upon closing of first qualified financing at option
Percentage of equity interest upon closing of first qualified financing at option of UC Regents
Customer A
Customer A.
Customer A [Member]
Certificates of Deposit [Member]
Certificates of Deposit
Other Noncurrent Assets [Member]
Other Assets
Two thousand fourteen plan.
Two Thousand Fourteen Plan [Member]
2014 401(k) Plan
Class of Warrant or Right [Table]
Class Of Warrant Or Right [Table]
Accounting Standards Update [Extensible Enumeration]
Area of Real Estate Property
Area of office and warehouse space
Entity Address, City or Town
Entity Address, City or Town
Operating Lease Amended Expiry Date
Operating Lease Amended Expiry Date
Amended lease expiry date
Five eight five eight horton street lease and two thousand twenty four expansion.
Five Eight Five Eight Horton Street Lease And Two Thousand Twenty Four Expansion [Member]
5858 Horton Street Lease and 2024 Expansion
Number of Reportable Segments
Number of reportable segments
Share based compensation arrangement by share based payment award stock overlapping offering period.
Share Based Compensation Arrangement By Share Based Payment Award Stock Overlapping Offering Period
Common stock overlapping offering period
Security Exchange Name
Security Exchange Name
Fair Value Measurements and Marketable Securities [Text Block]
Fair value measurements and marketable securities.
Fair Value Measurements and Marketable Securities
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]
Principal outstanding
Long-Term Debt, Gross
Carrying Amount
Total
Property, Plant and Equipment, Gross
Property, Plant and Equipment, Gross, Ending Balance
Property, Plant and Equipment, Gross, Beginning Balance
Total property and equipment
Property, Plant and Equipment, Gross, Total
Deferred Offering Costs
Unpaid debt issuance costs
Collaboration and License Agreement
Collaboration and License Agreement [Member]
Collaboration and License Agreements
Counterparty Name [Axis]
Counterparty Name
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Number of Shares Underlying Outstanding Options, Options vested and expected to vest at June 30, 2026
Concentration Risk Type [Domain]
Concentration Risk Type
Debt Issuance Costs, Current, Net
Debt Issuance Costs, Current, Net, Total
Debt issuance costs
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Other risks and uncertainties.
Other Risks And Uncertainties Policy Policy [Text Block]
Other Risks and Uncertainties
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Statistical Measurement [Domain]
Statistical Measurement
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price
Assets, Current
Total current assets
Share-Based Payment Arrangement, Expense
Total stock-based compensation expense
Share based compensation arrangement by share based payment award number of duration purchase period.
Share Based Compensation Arrangement By Share Based Payment Award Number Of Duration Purchase Period
Number of duration purchase period
Government Grants Cofunding Commitment Amount
Government grants cofunding commitment amount.
Government grants cofunding commitment amount
Document Period End Date
Document Period End Date
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Two thousand twenty equity incentive award plan.
Two Thousand Twenty Equity Incentive Award Plan [Member]
2020 Equity Incentive Award Plan
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Number of Shares Underlying Outstanding Options, Options exercisable at June 30, 2026
Loss on disposal of property and equipment
Gain (Loss) on Disposition of Property Plant Equipment
Gain (Loss) on Disposition of Property Plant Equipment, Total
Loss on disposal of property and equipment
Biotechnology Value Fund, L.P.
Biotechnology Value Fund, L.P. [Member}
Biotechnology Value Fund, L.P.
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSU)
Restricted Stock Units Subject to Future Vesting
Antidilutive Security, Excluded EPS Calculation [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Other comprehensive loss:
Class of Stock [Axis]
All Other Costs [Member]
All other costs.
All Other Costs
Debt Securities, Available-for-Sale, Realized Gain (Loss)
Realized gains or losses on marketable securities
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total
Debt Instrument, Capped Interest Rate
Debt instrument, capped interest rate.
Debt instrument, capped interest rate
Pre-funded warrants.
Pre-funded Warrants [Member]
Pre-funded Warrants
Other Directors or Officers [Member]
Other directors or officers.
Other Directors or Officers
Liabilities
Total liabilities
Lessee, Operating Lease, Discount Rate
Weighted-average discount rate
Operating lease, discount rate
Continuous period where the Company ceases to develop or commercialize any product.
Continuous Period Where Company Ceases To Develop Or Commercialize Any Product
Continuous period where the Company ceases to develop or commercialize any product
Financial Instruments [Domain]
Lessee, Operating Lease, Liability, to be Paid, Year Two
2028
Equipment costs.
Equipment Costs
Equipment costs
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average shares outstanding used in computing net loss per share, diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Securities Act File Number
Entity File Number
Number of capsids.
Number of Capsids
Number of capsids
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Net unrealized gain (loss) on marketable securities
Net unrealized gain (loss) on marketable securities
Common Stock Warrants
Common stock warrants.
Common Stock Warrants [Text Block]
Cover [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Expected volatility, minimum
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]
Summary of Carrying Value of Hercules Loan Facility
Additional investment amount subject to specific clinical milestone and at option of company
Additional Investment Amount Subject to Specific Clinical Milestones and at Option of Company
Additional investment amount subject to specific clinical milestones and at option of company.
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Canceled/Forfeited
Canceled/Forfeited
Revenue Benchmark [Member]
Revenue
Scenario [Domain]
US Treasury Securities [Member]
U.S. Treasuries
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Number of shares authorized and reserved for issuance
Number of shares authorized
Number of Operating Segments
Number of operating segments
Sale of Stock [Domain]
Sale of Stock
Segment Information
Segment Reporting Disclosure [Text Block]
General and Administrative Expense
General and administrative
General and Administrative Expense, Total
Exercise of options issued and outstanding and future vesting of restricted stock units.
Employee Options Issued and Outstanding and Future Vesting of Restricted Stock Units [Member]
Exercise of Stock Options Issued and Outstanding and Future Vesting of Restricted Stock Units
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Fair value assets level one and level two transfers amount.
Fair Value Assets Level One And Level Two Transfers Amount
Assets, Level 1 and Level 2 transfers
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Summary of Maturities of Lease Liabilities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Contract with Customer, Liability, Current
Deferred revenue
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Vesting period
Warehouse lease agreement.
Warehouse Lease Agreement [Member]
Warehouse Lease Agreement
Warrant shares, exercised
Number Of Warrant Shares Exercised
Number of warrant shares exercised.
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free interest rate, minimum
Depreciation
Depreciation expense
Depreciation, Total
Proceeds from Issuance of Long-Term Debt
Proceeds from Issuance of Long-Term Debt, Total
Proceeds from long-term debt, net of discount and issuance costs
Collaboration and License Revenue.
Collaboration And License Revenue [Member]
Collaboration and License Revenue
Collaborative arrangements future sales based milestone payment multiples.
Collaborative Arrangements Future Sales Based Milestone Payment Multiples
Future sales-based milestone payments multiples
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, shares, outstanding
Common Stock, Shares, Outstanding
Common Stock, Shares, Outstanding, Ending Balance
Operating Lease, Liability, Current
Operating lease liabilities, current portion
Less: Current portion of operating lease liabilities
Less: Current portion of operating lease liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue, Remaining Performance Obligation, Amount
Remaining performance obligations
Aggregate amount of transaction price allocated to remaining performance obligation
PreFunded warrants one.
PreFunded Warrants One [Member]
PreFunded Warrants Issued in Exchange of Common Stock [Member]
Document Transition Report
Document Transition Report
Unallocated Personnel Costs [Member]
Unallocated personnel costs.
Unallocated Personnel Costs (Including Stock-based Compensation)
Operating Expenses
Total operating expenses
Research and Development Expense
Research and Development Expense, Total
Direct research and development expenses for 4D-150
Research and development expenses
Statement of Cash Flows [Abstract]
Stock Issued During Period, Value, New Issues
Issuance of common stock upon ATM offering, net of issuance costs
Issuance of common stock for the offering program, net of issuance costs
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Summary of Stock Options Activity
Equity [Text Block]
Common Stock
Earnings Per Share [Text Block]
Net Loss Per Share, Basic and Diluted
Shares, Issued
Shares, Issued, Ending Balance
Shares, Issued, Beginning Balance
Number of shares priced under public offering
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Summary of Restricted Stock Units (RSU)
Computer Equipment [Member]
Computer Equipment and Software
Net loss
Net loss
Collaboration receivable
Collaboration Receivable Current
Collaboration receivable current.
Revenue from Clinical Trials and Other Studies Performance Obligations
Revenue from clinical trials and other studies performance obligations.
Revenue from clinical trials and other studies performance obligations
Operating Lease, Cost
Operating Lease, Cost
Operating lease cost
Potential cash payment for sales milestones
Potential Cash Payment upon Achievement of Certain Late-Stage Sales Milestones
Potential cash payment upon achievement of certain late-stage sales milestones.
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Purchase Obligation
Purchase Obligation, Total
Non-cancellable purchase obligations
Cystic Fibrosis Foundation Agreement.
Cystic Fibrosis Foundation Agreement [Member]
CFF Agreement
Operating Lease, Payments
Cash used in operating activities
Assets [Abstract]
Assets
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Construction in Progress [Member]
Construction in Progress
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Prepaid expenses and other current assets
Document Fiscal Year Focus
Document Fiscal Year Focus
Two Thousand Twenty Equity Incentive Award Plan And Two Thousand Twenty Five Employment Inducement Award Plan [Member]
Two thousand twenty equity incentive award plan and two thousand twenty five employment inducement award plan.
2020 Equity Incentive Award Plan and 2025 Employment Inducement Award Plan
Concentration Risk Benchmark [Domain]
Concentration Risk Benchmark
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Deferred revenue, estimated performance period
Deferred revenue expected to be recognized over period
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Cash flows from investing activities
Retirement Benefits [Abstract]
Accounts Payable, Current
Accounts payable
Accounts Payable, Current, Total
Due to/from customer
Research and Development Expense [Member]
Research and Development
Direct Research and Development Expenses
Schedule of common shares reserved for future issuance [Table Text Block]
Schedule Of Common Shares Reserved For Future Issuance [Table Text Block]
Schedule of Common Shares Reserved for Future Issuance
Loan Facility Amount
Loan facility amount.
Loan facility amount
Increase (Decrease) in Other Noncurrent Assets
Other assets
Other non-current assets
Research and Collaboration Arrangements.
Research And Collaboration Arrangements [Abstract]
Deferred Revenue
Deferred revenue
Deferred Revenue, Total
Commitments and Contingencies Disclosure [Abstract]
2027
Lessee, Operating Lease, Liability, to be Paid, Year One
Sale of Stock, Consideration Received on Transaction
Investment in redeemable convertible preferred stock financing
Net Income (Loss) Available to Common Stockholders, Basic
Net loss
Net Income (Loss) Available to Common Stockholders, Basic, Total
Fair value assumptions probability of change in control event percentage.
Fair Value Assumptions Probability Of Change In Control Event Percentage
Change in control event percentage
Debt Instrument [Axis]
Share-Based Payment Arrangement [Abstract]
Assets
Assets, Fair Value Disclosure
Assets, Fair Value Disclosure, Total
Fair Value
Sale of Stock [Axis]
Sale of Stock
Concentration Risk, Percentage
Concentration risk, percentage
Revenues
Total revenue
Total revenue
Revenue
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by investing activities
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Amortized Cost Basis
Cash, Money Market Funds and Available For Sale Debt Securities Amortized Cost Basis
Cash, money market funds and available for sale debt securities amortized cost basis.
Cash, money market funds and available for sale debt securities amortized cost basis
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Derivative Liability
Amount obligated to pay upon closing first qualified financing at option.
Amount Obligated To Pay Upon Closing First Qualified Financing At Option
Amount obligated to pay upon closing first qualified financing at option of UC Regents
Money Market Funds [Member]
Money Market Funds
5980 Horton Street.
Five Nine Eight Zero Horton Street [Member]
5980 Horton Street Building Lease
Income Tax Disclosure [Text Block]
Income Taxes
Debt Securities, Available-for-Sale, Allowance for Credit Loss
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance
Allowance for credit loss
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Initial payment received from CIRM
Initial Payment Received from Government Grant
Initial payment received from government grant.
Class of Warrant or Right [Line Items]
Class Of Warrant Or Right [Line Items]
Debt instrument extended term
Debt Instrument Extended Term
Debt instrument extended term.
Maximum unrealized loss at individual instrument level.
Maximum Unrealized Loss at Individual Instrument Level
Maximum unrealized loss at individual instrument level
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2026 (remaining six months)
Document Information [Table]
Other Liabilities, Noncurrent
Other liabilities
Total other liabilities, noncurrent
Aevitas therapeutics, Inc. agreement.
Aevitas Therapeutics Inc Agreement [Member]
Aevitas Therapeutics, Inc. Agreement
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities
Commitment and contingencies.
Commitment And Contingencies [Line Items]
Commitment And Contingencies [Line Items]
Property, Plant and Equipment [Table Text Block]
Schedule of Property and Equipment, Net
Income Tax Disclosure [Abstract]
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Additional Paid-in Capital [Member]
Additional Paid-in Capital
Series C Redeemable Convertible Preferred Stock.
Series C Redeemable Convertible Preferred Stock [Member]
Series C Redeemable Convertible Preferred Stock
Measurement Frequency [Domain]
Measurement Frequency
Statement of Income Location, Balance [Axis]
Income Statement Location
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Trading Symbol
Trading Symbol
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment, Net
Related Party Transaction [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Unpaid costs from ATM offering program in accrued and other current liabilities
Unpaid costs from ATM offering program in accrued and other current liabilities
UnpaidcostsfromATMofferingprograminaccruedandothercurrentliabilities.
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free interest rate, maximum
Award From Regenerative Medicine Institute [Line Items]
Award from regenerative medicine institute.
Employee-related Liabilities, Current
Payroll and related expenses
Employee-related Liabilities, Current, Total
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Cash flows from financing activities
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term
Fair Value, Recurring [Member]
Fair Value on Recurring Basis
Lessee, Operating Lease, Liability, to be Paid
Future minimum lease payments
Total future minimum lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: Amount representing interest
Less: Amount representing interest
Fair value assumptions change of control payment.
Fair Value Assumptions Change Of Control Payment
Change of control payment
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate
Percentage of maximum contributions of employee's eligible compensation
Equity Components [Axis]
Equity Components
Research and Development Expense (Excluding Acquired in Process Cost)
Research and development
Total research and development expenses
Deferred revenue.
Deferred Revenue [Member]
Deferred Revenue
Percentage of Facility Fee for Subsequent Borrowings
Percentage of facility fee for subsequent borrowings.
Percentage of facility fee for subsequent borrowings
Nonoperating Income (Expense)
Total other income, net
Equity Component [Domain]
Equity Component
Asset Class [Axis]
Asset Class
Accrued and other current liabilities.
Accrued And Other Current Liabilities [Text Block]
Accrued and Other Current Liabilities
Alpha-1 Antitrypsin (AAT) Deficiency [Member]
Alpha-1 antitrypsin (AAT) deficiency.
Alpha-1 Antitrypsin (AAT) Deficiency
Machinery and Equipment [Member]
Machinery and Equipment
Issuance of common stock - 2020 ESPP (in shares)
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Customer [Axis]
Customer
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Stock options exercisable period
Fair value assumptions probability of change in control discount rate.
Fair Value Assumptions Probability Of Change In Control Discount Rate
Change in control discount rate
Depreciation, Depletion and Amortization, Nonproduction
Depreciation and amortization
Depreciation, Depletion and Amortization, Nonproduction, Total
Common Stock, Voting Rights
Common stock voting rights
Statement of Comprehensive Income [Abstract]
Maximum [Member]
Maximum
Statistical Measurement [Axis]
Statistical Measurement
Contract with Customer, Liability, Noncurrent
Deferred revenue, net of current portion
Common Stock, Value, Issued
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Total
Common stock, $0.0001 par value, 300,000,000 shares authorized at June 30, 2026 and December 31, 2025; 55,214,097 and 57,607,874 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Number of financial institutions where cash is held.
Number Of Financial Institutions Where Cash Is Held
Number of financial institutions cash is held
Actual award payment period upon first commercial sale of product.
Actual Award Payment Period Upon First Commercial Sale Of Product
Actual award payment period upon first commercial sale of product
Five eight five eight horton street lease and two thousand eighteen expansion.
Five Eight Five Eight Horton Street Lease And Two Thousand Eighteen Expansion [Member]
5858 Horton Street Lease and 2018 Expansion
License arrangements.
License Arrangements [Abstract]
Stock issued during period value stock options exercised and vesting of restricted stock units.
Stock Issued During Period Value Stock Options Exercised And Vesting of Restricted Stock Units
Issuance of common stock upon exercise of stock options and vesting of RSUs
Unpaid research and development expense
Unpaid Research and Development Expense
Unpaid research and development expense.
Percentage of prepayment premium
Percentage of Prepayment Premium
Percentage of prepayment premium.
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Lender Name [Axis]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Derivative Financial Instruments, Liabilities [Member]
Derivative Liability
Entity Registrant Name
Entity Registrant Name
Long Term Debt
Debt Disclosure [Text Block]
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Gross Unrealized Losses
Customer Concentration Risk [Member]
Customer Concentration Risk
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Deferred grant reimbursement income
Deferred Grant Reimbursement Income
Deferred grant reimbursement income.
Summary of significant accounting policies.
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Other Nonoperating Income (Expense)
Other income (expense), net
Other Nonoperating Income (Expense), Total
Subsequent Events [Abstract]
Income Tax Expense (Benefit)
Provision for income tax
Income Tax Expense (Benefit), Total
Measurement Frequency [Axis]
Measurement Frequency
Contract with Customer, Receivable, after Allowance for Credit Loss
Accounts receivable
Contract with Customer, Receivable, after Allowance for Credit Loss, Total
Issuance of common stock upon public offering, net of issuance costs
Aggregate net proceeds, after deducting underwriting discounts and commissions and offering costs
Net proceeds after deducting issuance costs
Issuance of common stock under the ATM offering program, net of issuance costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk
Increase (Decrease) in Derivative Liabilities
Change in fair value of derivative liability
Liability Class [Axis]
Liability Class
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated other comprehensive gain (loss)
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Property, Plant, and Equipment, Total
Acquisition of property and equipment
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Awarded
Unpaid debt offering costs in accounts payable
Unpaid Debt Offering Costs In Accounts Payable
Unpaid debt offering costs in accounts payable.
Assets
Total assets
Property, Plant and Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Income Statement [Abstract]
Retirement Plan Name [Domain]
Retirement Plan Name
Gain Or Loss On Increase In Carrying Value Of Right Of Use Asset
Gain Or Loss On Increase In Carrying Value Of Right Of Use Asset
Gain or loss on increase in carrying value of right of use asset
Hercules Capital, Inc [Member]
Hercules Capital, Inc.
Hercules Capital, Inc
Commitment and contingencies.
Commitment And Contingencies [Table]
Commitment And Contingencies [Table]
ATM offering program.
Atm offering program
ATM offering program
ATM Offering Program
Issuance of common stock for the offering program, net of issuance costs (in shares)
Number of shares sold and issued
Issuance of common stock upon ATM offering, net of issuance costs (in shares)
Customer B.
Customer B [Member]
Customer B
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Vested
Vested
Earnings Per Share, Diluted
Net loss per share, diluted
Earnings Per Share, Diluted, Total
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule Of Disaggregated Amounts That Comprise Research and Development Expenses
Deferred Grant Reimbursements
Deferred grant reimbursements.
Deferred grant reimbursements
Dividends, Common Stock
Common stock dividend
Dividends, Common Stock, Total
Non-refundable license fee payable every year after execution until sales of a licensed product are made and royalties paid.
Non Refundable License Fee Payable Every Year After Execution
Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties
City Area Code
City Area Code
Government grant reimbursement income
Government Grants Reimbursement Income
Government grants reimbursement income
Aggregate principal amount of debt
Debt Instrument, Face Amount
Line of Credit Facility, Maximum Borrowing Capacity
Maximum borrowing capacity
Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]
Leerink Partners LLC
Leerink Partners Limited Liability Company [Member]
Leerink Partners Limited Liability Company.
Counterparty Name [Domain]
Counterparty Name
Variable Lease, Cost
Variable Lease, Cost
Variable lease cost
Issuance of common stock - 2020 ESPP
Stock Issued During Period, Value, Employee Stock Purchase Plan
Operating Lease, Weighted Average Remaining Lease Term
Weighted-average remaining lease term (in years)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Income [Extensible List]
Segment Reporting Information [Line Items]
Lease Expiration Date
Lease extended term date
Option exercise fees per selected capsid payable to related party.
Option Exercise Fees Per Selected Capsid Payable To Related Party
Option exercise fees per selected capsid
Lease, Cost
Total
Total
Retirement Plan Name [Axis]
Retirement Plan Name
Derivative Liability, Subject to Master Netting Arrangement, before Offset
Estimated fair value of derivative liability
Derivative Liability, Fair Value, Gross Liability, Total
Collaborative arrangement royalties multiples on actual award received.
Collaborative Arrangement Royalties Multiples On Actual Award Received
Royalties multiples on actual award received
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Property and equipment, net
Property and equipment, net
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Cash and cash equivalents, end of period
Cash and cash equivalents, beginning of period
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Operating Income (Loss)
Loss from operations
Retained Earnings [Member]
Accumulated Deficit
Cash and Cash Equivalents [Axis]
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation expense
Share-based Payment Arrangement, Noncash Expense, Total
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Aggregate fair value of marketable securities in a continuous loss position for less than twelve months
Operating Lease, Weighted Average Discount Rate, Percent
Weighted-average discount rate
Operating Lease, Liability, Noncurrent
Operating lease liabilities, long-term portion
Long-term portion of operating lease liabilities
Fair Value, Inputs, Level 1 [Member]
Level 1
Class of Stock [Line Items]
Class Of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by financing activities
Lease, Cost [Table Text Block]
Summary of Components of Lease Expense
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Other income (expense):
Nonoperating Income (Expense) [Abstract]
Derivative Liability, Noncurrent
Derivative liability
Earnings Per Share Reconciliation [Abstract]
Numerator
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Outstanding Shares of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share
Corporate Debt Securities [Member]
Corporate Bonds
Debt Securities, Available-for-Sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Research and Development, Contract to Perform for Others [Table]
Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]
Increase (Decrease) in Contract with Customer, Liability
Deferred revenue
Statement of Income Location, Balance [Domain]
Income Statement Location
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Cash flows from operating activities
Furniture and Fixtures
Furniture and Fixtures [Member]
Accretion (Amortization) of Discounts and Premiums, Investments
Net accretion of discount on marketable securities
Total amount of award under agreement.
Total Amount Of Award Under Agreement
Collaborative arrangement total amount of award
Exchange agreement.
Exchange Agreement [Member]
Exchange Agreement
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Change in fair value
Annual royalty
Annual royalty.
Annual Royalty
Funding agreement.
Funding Agreement [Member]
Funding Agreement
Schedule of Concentration of Risk
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Line of Credit Facility, Current Borrowing Capacity
Current borrowing capacity
Entity Tax Identification Number
Entity Tax Identification Number
Revenues [Abstract]
Revenue:
Long-Term Debt, Type [Axis]
Debt instrument term
Debt Instrument, Term
Two Thousand and Twenty Five Offering [Member]
Two thousand and twenty five offering.
2025 Offering
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
The Company
Local Phone Number
Local Phone Number
Related Party Transaction [Domain]
Related Party Transaction
Two thousand twenty employee stock purchase plan.
Two Thousand Twenty Employee Stock Purchase Plan [Member]
2020 ESPP
2020 Employee Stock Purchase Plan
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Denominator
Issuance of Common Stock upon Exercise of Stock Options
Issuance of common stock upon exercise of stock options.
Issuance of common stock upon exercise of stock options
Exchange of common stock for pre-funded warrants (in shares)
Stock Issued During Period Shares Of Common Stock For Pre-funded Warrant Conversions
Stock issued during period shares of common stock for pre-funded warrant conversions.
Accounting Policies [Abstract]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax
Collaboration and license revenue
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Customer.
Customer Member
Customer
Lessee, Operating Lease, Liability, to be Paid, Year Four
2030
Class of Stock [Domain]
Commercial Paper [Member]
Commercial Paper
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Number of Shares Available for Grant, Balances at June 30, 2023
Number of Shares Available for Grant, Balances at December 31, 2022
Number of shares available for future grants
Office Equipment [Member]
Office Equipment
Accrued Professional Fees, Current
Consulting and outside services
Stock, Class of Stock [Table]
Schedule Of Stock By Class [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company
Term Loans Aggregate Principal Amount Tranches Through June 15, 2027
Term Loans Aggregate Principal Amount Tranches Through June 15, 2027 [Member]
Term Loans Aggregate Principal Amount Tranches Through June 15, 2027.
Potential Cash Payment upon Achievement of Certain Late-Stage Development Milestones
Potential cash payment upon achievement of certain late-stage development milestones.
Potential cash payment for development milestones
Accounting standards update 2025-10.
Accounting Standards Update 2025-10 [Member]